September 26, 2021
1 min read
9 important updates in blood cancer treatment, research
September is Blood Cancer Awareness Month.
In conjunction with this observance, Healio highlights important research or treatment related to leukemia, lymphoma, multiple myeloma and myeloproliferative neoplasms.
- Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines. Read more.
- Convalescent plasma treatment appeared associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19. Read more.
- Eprenetapopt with azacitidine exhibited encouraging activity as posttransplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia. Read more.
- The FDA approved zanubrutinib for adults with Waldenström macroglobulinemia. Read more.
- A free nurse navigation service helped overcome barriers to clinical trial enrollment for patients with blood cancer. Read more.
- Pembrolizumab (Keytruda, Merck) plus gemcitabine, vinorelbine and liposomal doxorubicin demonstrated substantial efficacy as second-line therapy among patients with relapsed or refractory classical Hodgkin lymphoma. Read more.
- Teclistamab (JNJ-64007957, Janssen) showed encouraging efficacy among patients with relapsed or refractory multiple myeloma. Read more.
- Healio spoke with hematologist-oncologists and transplant physicians about improved outcomes with hematopoietic stem cell transplantation, decreases in HSCT complications based on advances in supportive care and conditioning regimens, promising treatments for graft-versus-host disease, and how greater access to transplantation is now potentially providing a curative option for older and frailer populations. Read more.
- Healio explored how oncologists, geneticists and researchers are collaborating to determine how CRISPR gene editing can produce more effective chimeric antigen receptor T cells that have the potential to be more durable, less costly and available on demand. Read more.